Connect with us

Cannabis News

Congresswoman Pushes Trump’s New Drug Czar To Back Full Marijuana Legalization And Follow ‘Science, Not Stigma’

Published

on

A Democratic congressman is pleading President Donald Trump has just been confirmed in the Senate as the White House drug czar following the science and proactively advocating for the full legalization of marijuana, beyond the additional cannabis rescheduling the president recently signed.

Rep. Dina Titus (D-NV), co-chair of the Congressional Cannabis Caucus, shared a link to a Marihuana Moment article on Tuesday about Sara Carter Bailey’s Senate confirmation vote as director of the Office of National Drug Control Policy (ONDCP).

Titus said Carter “must commit to common sense and evidence-based cannabis policy.”

“This includes descheduling marijuana and fully implementing my Evidence-Based Drug Policy Act so that federal decisions are guided by science, not stigma,” he said.

Titus and Cannabis Caucus Co-Chair Rep. Ilhan Omar (D-MN) announced in April that they had introduced the Evidence-Based Drug Policy Act, aiming to remove the legal restriction that prevents the drug czar from supporting the legalization of marijuana or other Schedule I drugs. The legislation has yet to advance in the GOP-controlled Congress, however.

Here is the text of the current law that would be repealed under the proposal:

“The Director . . . shall ensure that federal funds appropriated to the Office of National Drug Control Policy shall not be expended for any study or contract related to the legalization (for medical use or any other use) of a substance listed in section I of section 812 of this title and shall take such measures as may be necessary to oppose any attempt to legalize the use (in any form) of a substance not listed in subparagraph (I)(B) of section 8 of section (I). The purpose of the Food and Drug Administration approved for medical use.

Carter, for his part, has previously spoken out in favor of access to medical marijuana, saying he has “no problem” with legalization, even though he may not personally agree with the policy.

A former journalist known for his coverage of drug cartels, the ONDCP director had previously informed senators that the administration. keeping “all options” on the table as he considered a proposal to reorganize marijuanawhile describing cannabis reform as a “bipartisan issue.”

Despite his personal ambivalence about the redistricting issue, Trump last month signed an executive order directing the attorney general to quickly complete the process of moving cannabis from Schedule I to III of the Controlled Substances Act (CSA).

Given the ONDCP director’s role in setting and carrying out the administration’s agenda on drug policy issues, Carter’s enthusiastic endorsement of medical cannabis in the past is welcome to advocates.

Sen. Cory Booker (D-NJ) raised the issue of cannabis reform with the then-candidate in September, saying the additional reform would be a “step in the right direction.”

“It would open the door to more scientific research, so if you were to be confirmed, how would you advise the American president on the reprogramming process going on?” he asked.

Carter said he shares Booker’s passion for the issue, which he described as “bipartisan.”

“If confirmed as director, I will comply with all federal laws and meet all legal responsibilities of ONDCP,” he said. “However, we will continue to work in depth with research and data. We will continue to do so and explore all options.”

Tuesday’s vote on confirmation was largely along party lines, with Sen. Rand Paul (R-KY) joining all Democrats in opposition, and all other Republicans in support.

While Carter has spoken often on a variety of marijuana policy issues (focusing on illegal trafficking and illegal growing operations on US soil, for example), his public comments have been limited about how he personally feels about the issue. In a 2024 episode of her podcast The Sara Carter Show, she noted that she makes a distinction between legally regulated and illegally supplied marijuana.

“I don’t have a problem if it’s legalized and controlled,” he said. “I mean, maybe I have my own issues with how I feel about it, but I think it’s a wonderful way to handle cannabis for medicine and medical reasons — especially for people with cancer and other diseases, you know — to manage the disease and the side effects of those drugs and diseases. So I’m not saying we should make it illegal.”

Last month, a Democratic senator temporarily he resisted the Republican majority’s attempt to advance Carter’s confirmationsaying he is among many “unqualified” candidates who threaten to “undermine the rule of law and our national security.”

Carter will be the second White House drug czar in a row to voice his support for medical marijuana Former President Joe Biden’s ONDCP Director Rahul Guptaworked as a consultant to cannabis businesses and oversaw the implementation of West Virginia’s medical marijuana program.

On his social media, Carter has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

Carter has separately sounded the alarm about the dangers of pesticides and other contaminants in the marijuana grown and sold by Chinese cartels…last year a House committee took up the matter.

Also last year, the ONDCP director discussed the issue with Derek Maltz, a then-retired Drug Enforcement Administration (DEA) official who served as the agency’s interim administrator before being confirmed. Trump’s perennial pick, Terrance Cole.

In an X post about his interview with Maltz, Carter said how “Chinese marijuana growing operations are using dangerous chemicals as pesticides.”


It’s Marijuana Moment tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

In 2022, U.S. Rep. Mike Garcia (R-CA) praised Carter, who worked with his office to draw attention to illegal grow operations in his district, leading to an investigation by local law enforcement.

Carter credited Congress, saying, “Your work to take down illegal marijuana seeds has prevented the cartels from exploiting your community, the people forced to work in it, and the (money).

In a 2021 interview with Fox News’ Sean Hannity, he also talked about his work with Garcia, including accompanying him on a helicopter, “a lot of sophisticated illegal farms worth billions of dollars.”

The posters “have become much bolder. They are not afraid to hide,” he said. “They don’t hide it because they don’t feel like they’ll ever be held accountable for it.”

In a sense, Carter seems to be implicitly suggesting that he supports regulated access to cannabis as a means to promote public safety and health. Whether and how this implied position will affect federal policy, now that it has been confirmed, remains to be seen.

On his social media, he has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Bloemteknik receives £2.5 million investment

Published

on

By

Foresight Group has announced a £2.5m investment in Bloemteknik Limited, a Cardiff-based supplier of precision LED lighting systems for commercial greenhouses and vertical farms.

The investment was made through British Business Bank’s Wales Investment Fund and Foresight’s Growth VCTs. The Investment Fund for Wales was launched in November 2023 by the UK government-backed British Business Bank to promote the provision of seed funding to small and medium-sized businesses across Wales. Bloem’s investment was led by appointed fund managers, Foresight, who oversee the Fund’s equity investments of up to £5m.

© Bloemteknik

The investment allows Bloem to scale its operations, strengthen its delivery capability and expand into new international markets. The partnership brings strategic support through board-level guidance, sector expertise and access to Foresight’s global network, helping Bloem build a strong, high-growth business rooted in South Wales.

James Fleet, CEO of Bloem, said: “Bringing GreenFingers to market simply wouldn’t have been possible without Foresight’s support. Their investment has allowed us to turn an ambitious concept into meaningful value for growers. GreenFingers creates a truly self-contained self-optimizing lighting ecosystem, with advanced algorithms to automatically adjust complementary LED spectrums in real-time to maintain consistent DLI in a balanced crop environment.”

Bethan Bannister, Chief Executive of National and Regional Investment Funds at the British Business Bank, said: “It is great to see how the Welsh Investment Fund is accelerating innovative businesses like Bloem’s to bring new products to market. Bloem’s development track record is impressive and with this funding supporting its strategic growth ambitions, we look forward to its success.”

Ashley Rogers, Investment Manager at Foresight, commented: “Bloem has shown strong early traction in a rapidly growing market with a differentiated product and an experienced team. We are excited to support their growth and innovation, especially as they expand into new geographies and continue to build their market-leading proposition.”

For more information:
Bloemteknik
Sophia House Cathedral Rd Cardiff CF11 9LJ, United Kingdom
+44 (0) 2920 660250
(email protected)
bloemteknik.com

Continue Reading

Cannabis News

Massachusetts Hits $10 Billion Marijuana Sales Milestone, With Top Official Saying Consumption Lounges Will Bolster Industry In 2026

Published

on

By

Massachusetts hit a 2025 marijuana sales milestone of $1.65 billion a year for adult use, bringing the state’s total cannabis purchases to more than $10 billion since the launch of the recreational market, officials announced Thursday.

A top regulator also said the addition of social consumption halls could give the industry another boost in 2026, and President Donald Trump’s directive to federally regulate cannabis will create more research opportunities in the state.

The Massachusetts Cannabis Control Commission (CCC) released the latest data on Thursday, saying officials are anticipating an even higher sales record this year as the state prepares. launching a new license category or social consumption venue.

By 2025, when recreational and medical sales are combined, the state could see about $1.8 billion in annual legal marijuana purchases. Overall, since 2018, there have been about $10.8 billion in combined sales of medical and recreational cannabis.

“Massachusetts’ cannabis industry continued to mature in 2025 as the number of cannabis businesses reached its highest point since adult-use sales began in 2018,” CCC President Shannon O’Brien said in a press release. “While gross sales remain high, the Commission will seek to remove regulatory barriers through the new Red Tape Commission in 2026, helping licensees stabilize and plan for the future as the industry continues to evolve.”

Travis Ahern, CCC Executive Director, he said Beyond the expansion of the social consumption arena, Trump’s order to move marijuana from Schedule I to III of the federal Controlled Substances Act (CSA) will bring benefits to the state.

“Commissioners and staff are working hard to prepare for a potential expansion of the social consumption industry and the possibility of new research opportunities should the federal government reschedule cannabis,” he said. “With critical changes on the horizon, the Commission continues to adapt its policies, protocols and oversight to continue building a safe, fair and efficient cannabis industry for Massachusetts.”

Marijuana merchants in Massachusetts registered a new annual record of 46.3 million transactions in 2025, the CCC said, up 3.4 million from the previous year.

In the background are Massachusetts election officials has organized a hearing to investigate a complaint challenging the signature collection process In support of the ballot initiative to roll back the state’s marijuana legalization law.

This came about two weeks after the Secretary of the Commonwealth Electoral Division confirmed the anti-cannabis campaign. it has collected enough signatures for the members of parliament to take action before potentially being put on the November ballot.

As detailed in the latest complaint, the campaign has been mired in controversy over allegedly deceptive signature-gathering tactics. Paid petitioners have been accused of using fake letters on other ballot measures, such as affordable housing and same-day voter registration.

The The state attorney general has confirmed that he has received complaints for that And a state association of marijuana companies urged voters to report them to local officials if they observe them Instances of “spoof mail” or other fraudulent solicitation tactics. The campaign has denied the allegations.

The office of Massachusetts Attorney General Andrea Campbell (D), that is He cleared the signature collection campaign in September—stressed to voters the importance of reading their summary, which should go at the top of the signature form, before signing any petition.

The Massachusetts legislature received the initiative for consideration Wednesday when the 2026 session began. Unless annulled, members of parliament have until May 5 to act on the proposal. If they decide not to pass it in the legislature, the campaign would have to go through another round of petitions and get at least 12,429 certified signatures by July 1 to get on the November ballot.

Meanwhile, the head of Massachusetts’ marijuana regulatory agency recently suggested measures to effectively recriminalize the sale of recreational cannabis. dangerous tax revenues being used to support substance abuse treatment efforts and other public programs.

Massachusetts lawmakers recently joined a bicameral conference committee to hammer out a deal. double the legal limit for possession of marijuana for adults and reviewing the regulatory framework for the state’s adult cannabis market.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

CCC has also launched a targeted online platform helping people find work, on-the-job training and networking opportunities in the state’s legal cannabis industry.

State legislators have also been pondering imposing stricter restrictions on intoxicating hemp-derived products and a plan allowing individual entities to control a greater number of cannabis establishments.

Also in Massachusetts Legislators working on state budgets butted heads with CCC officialswho said critical technology improvements can’t be made without more money from the legislature.

Massachusetts lawmakers also passed a bill establishing a pilot program for the regulated therapeutic use of psychedelics. And two committees Hearings to discuss additional measures related to psilocybin were held separately.

user photo Brian Shamblen.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

CEO of Medicinal Cannabis Authority calls for alignment in Pharmacy Bill

Published

on

By











The Chief Executive Officer (CEO) of the Medicinal Cannabis Authority participated in the initial consultations on Antigua and Barbuda’s new Pharmacy Act, stressing the need to resolve conflicts between existing pharmacy regulations and medicinal cannabis legislation.

Regis Burton explained that the presence in the Parliament building was necessary because of the overlaps between the work of the Pharmacy Act and the Medicinal Cannabis Authority (MCA), particularly as the current Pharmacy Regulations were last amended in 2012.

“I’m here representing the Medicinal Cannabis Authority, where there is some degree of overlap between what happens in the Pharmacy Act and the Pharmacy Regulations,” Burton said. The Director General emphasized the importance of incorporating the advances in cannabis science into updated pharmaceutical regulations, noting that the MCA is the central regulatory body for medicinal cannabis in the country.

“It is important that as the development of the pharmaceutical industry progresses, we also incorporate new knowledge, the new science of medicinal cannabis,” he said. “So I’m here today, as an industry professional, to make sure I can share some developments in the cannabis industry that maybe not too many people know about.”

Read more at The Observer of Antigua










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media